Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors
A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.
Scaffold-based design and synthesis of potent N-type calcium channel blockers
The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optim
METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS
A method of increasing the bioavailability of a compound of formula 1 by orally administering to a patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, with food:
-
(2009/12/27)
Calcium channel blockers comprising two benzhydril moieties
Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
-
(2008/06/13)
CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES
Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
-
(2008/06/13)
More Articles about upstream products of 41332-24-5